Trial Profile
Evaluation of the Clinical and Economic Outcomes Associated With Exenatide Versus Basal Insulin in People With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Feb 2018
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Insulin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 01 Feb 2018 Primary endpoint (Changes from baseline in composite outcomes of HbA1c7.0% and weight reduction) has been met as per the results published in the Diabetes Therapy.
- 01 Feb 2018 Primary endpoint (Changes from baseline in HbA1c (%)) has not been met as per the results published in the Diabetes Therapy.
- 01 Feb 2018 Primary endpoint (Changes from baseline in weight (kg)) has been met as per the results published in the Diabetes Therapy.